Maximizing research impact via insightful peer-review

Breaking News

New Impact factor is 5.168

Oncotarget’s rising popularity is due to insightful, constructive, punctual, multiple peer-review: helping our authors to increase the impact of their research

Multidisciplinary and Mega-Journals

Title IF(2016)
Nature Communications 12.124
EMBO J 9.792
EMBO Rep 8.568
Cell Reports 8.282
e-Life 7.725
Oncotarget 5.168
Mol Cell Biol 4.398
Scientific Reports 4.259
FEBS Letters 3.623
PLOS ONE 2.806

2016 Collection of Priority papers

Oncotarget In The News

Oncotarget is accepting papers on topics beyond oncology: Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, Pharmacology (all areas) and more

Impact factor (IF) Thomson Reuters JCR

Year IF Total Cites
2016/2017 5.168 30241
2015 5.008 10452
2014 6.359 3908
2013 6.627 2217
2012 6.636 1450
2011 4.784 493

2015/2016: 5-Year Impact Factor: 5.415

Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine (subject area) and Oncology

Oncotarget ranks number 1 on Total Documents (2015-2016) among all journals in Oncology, see here

If your paper was mistakenly rejected by other leading journals, you may submit it to Oncotarget together with peer-reviews obtained from the other journal and rebuttal letter.

The term "oncotarget" encompasses all molecules, pathways, and cellular functions common in cancer and aging, neurodegeneration and atherosclerosis, lymphocytes and neurons, cancer cells and microbes.

Oncotarget is a multidisciplinary traditional journal with free-access. Oncotarget publishes papers online in weekly issues. Each issue or paper can be printed for special demand.

Our mission is to make scientific results rapidly and widely available. To maximize the impact of research via insightful review. To allow exceptional discoveries to be shared quickly. To eliminate the border between specialties. To link different fields of biomedical science. To foster applications of basic and clinical science to fight disease.

Under the leadership of the most prominent scientists, the journal helps all researchers contribute to the progress of science. Life without disease is our ultimate goal.

The success of Oncotarget has prompted us to launch sections beyond oncology.

250 Plus Papers from the Editorial Board:
See full list

Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC